V. Alberola

发表

Genetic testing for chemotherapy in non-small cell lung cancer.

E. Felip, R. Rosell, M. Taron, 2003, Lung cancer.

Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer.

J. Padilla, E. Felip, R. Rosell, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Low ERCC 1 Expression Correlates with Prolonged Survival after Cisplatin plus Gemcitabine Chemotherapy in Non-Small Cell Lung Cancer 1

D. Gandara, R. Rosell, K. Danenberg, 2002 .

Lung cancer and treatment in elderly patients: the Achilles Study.

R. Rosell, N. Viñolas, M. Provencio, 2009, Lung cancer.

Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.

D. Gandara, E. Felip, L. Paz-Ares, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.

M. Taron, M. Santarpia, M. Sánchez-Ronco, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer.

J. Garcia-conde, R. Rosell, V. Alberola, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.

J. Pujol, A. Monnier, J. Douillard, 1994, Seminars in oncology.

Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer.

V. Alberola, E. Cortesi, Ó. Juan, 2002, Critical reviews in oncology/hematology.

Intratumoral variation of estrogen and progesterone receptors in breast cancer: relationship with histopathological characteristics of the tumor.

E. Vizcarra, J. Garcia-conde, A. Lluch, 1990, Oncology.

Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.

A. Carrato, E. Felip, L. Paz-Ares, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

C. García-Girón, R. Rosell, M. Taron, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

A. Carrato, R. Salazar, C. García-Girón, 2021, Drugs & Aging.

Determinants of response and resistance to cytotoxics.

R. Rosell, M. Monzó, M. Taron, 2002, Seminars in oncology.

Iron deficiency in patients with solid tumours: prevalence and management in clinical practice

P. Gascón, V. Alberola, J. Muñoz-Langa, 2014, Clinical and Translational Oncology.

Randomized P hase I II S tudy o f G emcitabine-Cisp latin Versus E toposide-Cispla tin i n t he T reatment o f L ocally Advanced o r M etastatic N on-Small-Cell L ung C ancer

A. Carrato, R. Rosell, B. Massuti, 1999 .

Clinical outcome of gemcitabine (gem)/cisplatin (cis)- vs docetaxel (doc)/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age.

M. Taron, O. Etxaniz, C. Camps, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.

P Chomy, J L Pujol, J. Pujol, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.

S. Barni, R. Ramlau, M. Mitrović, 2005, Lung cancer.

The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patients

I. Marugán, J. Garcia-conde, F. España, 1989, Cancer.

Epidermal growth factor in human breast cancer, endometrial carcinoma and lung cancer. Its relationship to epidermal growth factor receptor, estradiol receptor and tumor TNM.

J. Garcia-conde, A. Lluch, V. Guillem, 1993, Clinica chimica acta; international journal of clinical chemistry.

Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (gv/iv) in advanced non-small cell lung cancer (NSCLC): final results of a Spanish lung cancer group phase III trial (GEPC/98-02)

R. Rosell, M. Provencio, C. Camps, 2001 .

Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.

R. Rosell, Jia Wei, M. Taron, 2010, Lung cancer.

Preoperative high-dose cisplatin versus moderate-dose cisplatin combined with ifosfamide and mitomycin in stage IIIA (N2) non small-cell lung cancer: results of a randomized multicenter trial.

E. Felip, J. Astudillo, P. Garrido, 2000, Clinical lung cancer.

Targeted therapy in combination with gemcitabine in non-small cell lung cancer.

G. Bepler, G. Scagliotti, F. de Marinis, 2003, Seminars in Oncology.

The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.

R. Rosell, J. Ramírez, C. Camps, 2006, Revue des maladies respiratoires.

Intratumoral variations in cytoplasmic estrogen receptor levels in breast cancer

A. Lluch, A. Antón, V. Alberola, 2005, Breast Cancer Research and Treatment.

Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.

D. Gandara, R. Rosell, K. Danenberg, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Measurement and impact of co-morbidity in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. A phase II study of weekly paclitaxel

V. Alberola, Ó. Juan, J. Campos, 2007, Acta oncologica.

Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study.

V. Carañana, V. Alberola, Ó. Juan, 2002, Japanese journal of clinical oncology.

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

A. Carrato, R. Rosell, B. Massuti, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study

A. Carrato, J. Tabernero, J. García-Foncillas, 2012, PloS one.

Prospective assessment of XRCC3, XPD and Aurora kinase A single-nucleotide polymorphisms in advanced lung cancer

B. Massuti, M. Provencio, C. Camps, 2012, Cancer Chemotherapy and Pharmacology.

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

E. Felip, R. Rosell, N. Viñolas, 2011, Lung cancer.

Methylation patterns and chemosensitivity in NSCLC.

M. Taron, J. Ramírez, M. Sánchez-Ronco, 2006, Advances in experimental medicine and biology.

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.

R. Rosell, M. Taron, J. Ramírez, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.

A. Carrato, E. Felip, R. Rosell, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.

A. Carrato, E. Felip, B. Massuti, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

R. Rosell, M. Monzó, Cristina Martín, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.

Antonio Nieto, Mariano Provencio, Bartomeu Massuti, 2012, Lung cancer.

Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.

R. Rosell, M. Taron, M. Sánchez-Ronco, 2004, Clinical lung cancer.

Ifosfamide-induced psychosis

V. Alberola, Ó. Juan, R. Hernández, 2004, Acta oncologica.

Value of CA 15.3 in breast cancer and comparison with CEA and TPA: A study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis

A. Lluch, V. Belloch, E. Vizcarra, 2005, Breast Cancer Research and Treatment.

Phase II trial of cisplatin and etoposide as first-line therapy in metastatic breast carcinoma.

J. Garcia-conde, A. Lluch, V. Alberola, 1994, Oncology.

A randomized, crossover comparison of standard-dose versus low-dose lenograstim in the prophylaxis of post-chemotherapy neutropenia

V. Carañana, V. Alberola, Ó. Juan, 2001, Supportive Care in Cancer.

Influence of the Cyto-Protective Agent Amifostine on the Pharmacokinetics of Low-Dose Paclitaxel

V. Alberola, Ó. Juan, A. Rocher, 2005, Chemotherapy.

Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma

V. Alberola, Ó. Juan, J. Sotillo, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.

R. Rosell, M. Monzó, V. Alberola, 1995, Seminars in oncology.

Predictors of long-term survival in patients with lung cancer included in the randomized Spanish Lung Cancer Group 0008 phase II trial using concomitant chemoradiation with docetaxel and carboplatin plus induction or consolidation chemotherapy.

R. Rosell, B. Massuti, P. Garrido, 2009, Clinical lung cancer.

Mechanism of suppression of the depressed lymphocyte response in lung cancer patients.

V. Alberola, J. Marín, A. Lluch, 1985, Allergologia et Immunopathologia.

Cisplatin/gemcitabine (CG) vs cisplatin/gemcitabine/vinorelbine (CGV) vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine (GV/IV) in advanced non-small cell lung cancer. Interim analysis of a Spanish Lung Cancer Group (SLCG) phase III trial

R. Rosell, M. Provencio, C. Camps, 2000 .

823 A full navelbine oral (NVB oral) treatment in combination with cisplatin (P) followed by NVB oral single agent as consolidation therapy in advanced non small-cell lung cancer (NSCLC)

S. Barni, R. Ramlau, M. Mitrović, 2003 .

Remission of Sézary's syndrome with cyclosporin A. Mild capillary leak syndrome as an unusual side effect.

A. Castells, V. Alberola, I. Betlloch, 1986, Acta dermato-venereologica.

Excision cross-complementing group 1 (ERCC1) single nucleotide polymorphisms (SNPs) and survival in cisplatin (cis)/docetaxel (doc)-treated stage IV non-small cell lung cancer (NSCLC) patients (p): A Spanish Lung Cancer Group study.

R. Rosell, M. Provencio, C. Camps, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

27 Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: A randomized trial by the Spanish lung cancer group

A. Carrato, A. Antón, V. Alberola, 1997 .

Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.

E. Felip, R. Rosell, N. Viñolas, 2011, Lung cancer.

Combined DNA repair gene single nucleotide polymorphisms (SNPs) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients (p).

R. Rosell, M. Taron, M. Sánchez-Ronco, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.

A. Carrato, A. Antón, V. Alberola, 2000, Lung cancer.

The influence of chemotherapy on plasma coagulation and fibrinolytic systems in lung cancer patients

I. Marugán, J. Garcia-conde, F. España, 1989, Cancer.